^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    fludarabine IV

    i
    Other names: NSC 312887, NSC-312887, NSC312887
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    15h
    Haplo-Cord HSCT for AML/MDS (clinicaltrials.gov)
    P=N/A, N=82, Recruiting, Fujian Medical University Union Hospital | N=180 --> 82
    Enrollment change
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • NPM1 (Nucleophosmin 1) • RUNX1 (RUNX Family Transcription Factor 1) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
    |
    NPM1 mutation • KIT mutation
    |
    cytarabine • cyclophosphamide • melphalan • fludarabine IV • busulfan
    16h
    A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial). (PubMed, Front Oncol)
    Patients received lymphodepleting chemotherapy (cyclophosphamide 30 mg/kg/day for 2 days and fludarabine 25 mg/m2/day for 5 days) followed by a single infusion of KITE-439 with daily IL-2 (2.5×105 IU/kg, up to 7 doses). These results suggest that KITE-439 has an acceptable safety profile for the treatment of patients with HPV-associated epithelial cancers. Further studies are needed to determine optimal manufacturing conditions and T-cell characteristics required for enhanced antitumor activity.
    P1 data • Journal
    |
    CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • IL7 (Interleukin 7)
    |
    cyclophosphamide • fludarabine IV • KITE-439
    17h
    An Open-label Study of GC012F in Rheumatoid Arthritis. (clinicaltrials.gov)
    P1, N=0, Withdrawn, Institute of Hematology & Blood Diseases Hospital, China | Initiation date: Jan 2026 --> Dec 2027 | Not yet recruiting --> Withdrawn
    Trial initiation date • Trial withdrawal
    |
    cyclophosphamide • fludarabine IV
    19h
    Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Phase classification: P1/2 --> P1
    Phase classification
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV • iC9-CAR19 cells • rimiducid (AP1903)
    1d
    Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL (clinicaltrials.gov)
    P1, N=19, Recruiting, University Health Network, Toronto | Trial completion date: May 2026 --> Jun 2028 | Trial primary completion date: Mar 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    1d
    Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Stanford University
    New P2 trial
    |
    TP53 (Tumor protein P53) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • MECOM (MDS1 And EVI1 Complex Locus) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    TP53 mutation
    |
    cyclophosphamide • fludarabine IV
    1d
    Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation (clinicaltrials.gov)
    P2, N=9, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=20 --> 9
    Enrollment closed • Enrollment change
    |
    clonoSEQ®
    |
    Opdivo (nivolumab) • Imbruvica (ibrutinib) • cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • fludarabine IV
    2d
    Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases (clinicaltrials.gov)
    P1, N=9, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China | Initiation date: Mar 2026 --> Jul 2026
    Trial initiation date
    |
    CD19 (CD19 Molecule) • MPO (Myeloperoxidase)
    |
    cyclophosphamide • fludarabine IV
    3d
    A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab (clinicaltrials.gov)
    P2, N=53, Recruiting, National Cancer Institute (NCI) | N=170 --> 53
    Enrollment change
    |
    Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • Young TIL
    3d
    GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours (clinicaltrials.gov)
    P1, N=30, Recruiting, Canadian Cancer Trials Group | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PGR (Progesterone receptor) • GPNMB (Glycoprotein Nmb)
    |
    PD-L1 expression • HER-2 negative
    |
    cyclophosphamide • fludarabine IV
    6d
    The Role of Hematopoietic Cell Transplantation in Ataxia-Telangiectasia. (PubMed, Pediatr Blood Cancer)
    The use of HCT for the treatment of immunodeficiency and relapsed/refractory hematologic malignancies in patients with A-T is not well described and understood. Current evidence is limited and heterogeneous, supporting its use only in select high-risk patients at specialized centers, with multicenter collaboration needed to define best practices.
    Review • Journal
    |
    ATM (ATM serine/threonine kinase)
    |
    fludarabine IV
    6d
    Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=24, Suspended, City of Hope Medical Center | Recruiting --> Suspended
    Trial suspension
    |
    Erbitux (cetuximab) • cyclophosphamide • fludarabine IV • CD19 CAR T cells